Core Diagnostics operates a clinical laboratory utilizing molecular techniques such as next-generation sequencing and flow cytometry to provide precise diagnostic solutions for hereditary and sporadic cancers, hematological disorders, and genetic diseases. The company addresses the need for accurate disease stratification and therapy selection, enabling healthcare providers to make informed treatment decisions.
Funding
Funding not disclosed
ICFounders
Product
Problem
Diagnostic testing for cancers, hematological disorders, and genetic diseases often lacks the precision needed for accurate disease stratification and optimal therapy selection. Traditional methods may not provide sufficient insight into the molecular characteristics of a disease, leading to uncertainty in treatment decisions.
Solution
Core Diagnostics operates a clinical laboratory that leverages advanced molecular techniques, including next-generation sequencing (NGS) and flow cytometry, to deliver precise diagnostic solutions. The company's comprehensive testing menu covers hereditary and sporadic cancers, hematological disorders, reproductive health, cardiovascular diseases, genetic endocrine disorders, kidney diseases, urological disorders, and neurological conditions. By applying molecular biology to medical testing, Core Diagnostics provides healthcare providers with detailed insights into the genome and proteome, enabling more informed treatment decisions and improved patient outcomes.
Target Audience
The primary audience includes oncologists, hematologists, endocrinologists, nephrologists, urologists, gynecologists, and other specialists requiring advanced diagnostic insights for accurate disease management, as well as patients seeking precise and early diagnoses.
Features
- Molecular diagnostics using liquid biopsies (ddPCR), PCR, rtPCR, qPCR, NGS, and Sanger Sequencing
- Immunohistochemistry (IHC) with dual pathologist review to enhance accuracy
- Flow cytometry for cell counting, sorting, biomarker detection, and Minimum Residual Disease (MRD) monitoring
- Histopathology with comprehensive biopsy reports reviewed by organ specialists, adhering to global guidelines
- Cytopathology with automated processes and international reporting standards (BETHESDA system)
- Cytogenetics with automated Karyotyping & FISH platforms and image-enhanced reporting
- Subscription plans for hypertension and diabetes management, including regular diagnostic monitoring tests
- Home collection services for patient convenience